DPP-4 inhibitors used to treat type 2 diabetes, this class includes different brands in single molecule or combined with other molecules like metformin.
DPP-4 inhibitors brands:
|Brand name||Active ingredient(s)|
|Janumet||sitagliptin and metformin|
|Janumet XR||sitagliptin and metformin extended release|
|Kombiglyze XR||saxagliptin and metformin extended release|
|Glyxambi||linagliptin and empagliflozin|
|Jentadueto||linagliptin and metformin|
|Kazano||alogliptin and metformin|
|Oseni||alogliptin and pioglitazone|
According to FDA, 33 cases of severe arthralgia have been reported with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors from October 16, 2006, approval date of the first DPP-4 inhibitor, through December 31, 2013.
Sitagliptin was the most frequently reported with 28 cases , followed by saxagliptin 5 cases , linagliptin 2 cases , alogliptin only 1 case and vildagliptin two cases.
Although the number of reported cases is very low compared to the patients who use DPP-4 inhibitors, you should report any severe joint pain or any other related symptoms to your health care professional.
To download the full FDA safety warning please follow this link :